Intramuscular olanzapine in the management of acute agitation

Annals of Pharmacotherapy

Volumn 38, Issue 12, 2004, Pages 2128-2135

  Tulloch, Karen J ^a   Zed, Peter J ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Faculty of Pharmaceutical Sciences   (Canada)

Author keywords

Agitation; Intramuscular; Olanzapine

Indexed keywords

HALOPERIDOL; LITHIUM; LORAZEPAM; OLANZAPINE; VALPROIC ACID;

AGITATION; AKATHISIA; BIPOLAR DISORDER; CLINICAL TRIAL; DEMENTIA; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; HUMAN; HYPOTENSION; MONOTHERAPY; MOTOR DYSFUNCTION; MULTIPLE DRUG DOSE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; INJECTIONS, INTRAMUSCULAR; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 12844265985     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E258     Document Type: Review

References (34)

1. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000;61(suppl 14):5-10.
2. Allen MH, Currier GC. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004;26:42-9.
3. Citrome L. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med 2002;112:85-96.
4. Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000;61(suppl 14): 11-20.
5. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP, Ross RW. The Expert Consensus Guideline Series: treatment of behavioral emergencies. Postgrad Med Special Report. 2001[May]:1-88. www.psychguides.com/ Behavioral%20Emergencies.pdf (accessed 2004 May 18).
6. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002;16:219-28.
7. McAllister-Williams RH, Ferrier IN. Rapid tranquilization: time for a reappraisal of options of parenteral therapy. Br J Psychiatry 2002;180:485-9.
8. Yildez A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;20:339-46.
9. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
10. Wright P Birkett M, David SR, Meehan K, Ferchand I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
11. Wright P, Lindborg S, Birkett M, Meehan K, Jones B, Alaka K, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003;48:716-21.
12. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97.
13. Meehan K, Wang H, David S, Nisivocca JR, Jones B, Beasley CM, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26:494-504.
14. Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25:1420-8.
15. Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62(suppl2):22-4.
16. Kay SR, Fisbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-7.
17. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21:192-8.
18. Eli Lilly and Company. Briefing information: NDA 21-253:Zyprexa (olanzapine M, Eli Lilly, Inc.). FDA Psychopharmacological Drugs Advisory Committee (2001 Feb 14). www.fda.gov/ohrms/dockets/ac/01/briefing/ 3685b1_01_lilly.pdf (accessed 2004 May 18).
19. Corrigan JD. Development of a scale for assessment of agitation following traumatic brain injury. J Clin Exper Neuropsychol 1989;11:261-77.
20. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989;44:M77-84.
21. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40.
22. Bienek SA, Ownby RL, Penalver A, Dominguez RA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998;18:57-62.
23. Salzman C, Green AI, Rodriquez-Villa F, Jaskiw GI. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986;27:79-91.
24. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1999;43(suppl 2 revised):25S-40S.
25. Murphy BE, Bagnall A, Chue P, Fenton M, Leitner M, Wood J. Loxapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Oxford: Update Software.
26. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2mg versus 10mg in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-8.
27. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001;155:128-34.
28. Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004;65:386-94.
29. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill A. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003;23:342-8.
30. Dear Healthcare Professional letter. Toronto, ON: Eli Lilly Canada, September 7, 2004.
31. Kerr IB, Taylor D. Acute disturbed or violent behavior: principles of treatment. J Psychopharmacol 1997;11:271-7.
32. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85. DOI 10.1345/aph.17215
33. Bellnier TJ. Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm 2002;59(suppl 5):S12-8.
34. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomized controlled trial. JAMA 2003;290:2693-702.